Clinical Trial

Cladribine Venetoclax in Monocytic AML

Name: Cladribine Venetoclax in Monocytic AML — clinical trial record (NCT06232655)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

Protocol Amendment History 3 changes

critical Enrollment closed, study ongoing 2026-08-01

notable Enrollment reduced: 20 -> 10 participants 2026-08-01

notable Primary completion moved earlier: 2026-10 -> 2026-06-03 2026-08-01

Trial Details

NCT Number	NCT06232655
Lead Sponsor	University of Colorado, Denver Collaborators: The Leukemia and Lymphoma Society
Conditions	Acute Myeloid Leukemia
Enrollment	10 participants
Start Date	2024-02-08
Primary Completion	2026-06-03 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-31